MENU

Asundexian: FDA Approval and OCEANIC-STROKE Trial Results

NeurologyLive USA
Overview
The FDA has approved asundexian (Sunharbo), the first factor XIa inhibitor for the secondary prevention of noncardioembolic ischemic stroke and high-risk TIA. In phase 3 trials, a 50 mg daily dose combined with antiplatelet therapy reduced ischemic stroke incidence to 6.2% compared to 8.4% for placebo without a significant increase in major bleeding.
In Depth

Key Findings

The FDA has approved Bayer’s asundexian (marketed as Sunharbo), an oral factor XIa (FXIa) inhibitor, to reduce the risk of recurrent stroke in adults following a noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). The approval is based on the phase 3 OCEANIC-STROKE trial, which demonstrated that asundexian 50 mg once daily, used in combination with antiplatelet therapy, significantly reduced the risk of ischemic stroke by 26% over a median treatment period of 14.2 months.

Technical Details

The double-blind OCEANIC-STROKE trial enrolled 12,327 patients (asundexian, n = 6162; placebo, n = 6165) randomized within 72 hours of a qualifying event. Eligible patients had an NIHSS score of 15 or less and presented with at least one of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging.

  • Primary Efficacy: Ischemic stroke occurred in 6.2% of the asundexian group vs 8.4% in the placebo group (HR 0.74; P <.001). Ischemic or hemorrhagic stroke occurred in 6.6% vs 8.8% (HR 0.74; P <.001).
  • Composite Outcomes: Cardiovascular death, myocardial infarction, or stroke occurred in 9.2% vs 11.1% (HR 0.83; P <.001). All-cause death, MI, or stroke occurred in 10.5% vs 12.3% (HR 0.85; P = .003).
  • Safety: ISTH-defined major bleeding occurred in 1.9% of asundexian patients vs 1.7% for placebo (HR 1.10; P = .46). Serious adverse events were reported in 19.2% vs 19.5%.

Background & Context

Non-cardioembolic ischemic strokes represent approximately 45% of the 12 million global annual strokes, with roughly 1 in 10 patients experiencing recurrence within one year despite guideline-recommended therapy. The 50-mg dose used in this trial was informed by the phase 2b PACIFIC-STROKE trial, which showed a signal for fewer symptomatic strokes, particularly in patients with atherosclerosis.

Significance & Outlook

Asundexian is the first FXIa inhibitor approved for secondary stroke prevention. Its use is limited to noncardioembolic stroke/high-risk TIA populations; it is not approved for atrial fibrillation and is not recommended for patients with moderate or severe hepatic impairment. Clinical labeling advises avoiding combined P-gp/strong CYP3A4 inducers and withholding the drug for at least 24 hours before elective procedures or after thrombolysis.

Source: https://www.neurologylive.com/view/fda-approves-asundexian-treatment-secondary-stroke-prevention

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC